Developmental Medicine & Child Neurology · 2013 · 35 citations · 14 references
MedicineNeurologyPediatricsAutism Spectrum DisordersEpilepsyPediatric NeurologyDisorders Of Phosphate MetabolismEpilepsy In ChildhoodMetabolic EpilepsiesNeurodevelopmental DisordersNeurogenetic DisordersPyridoxine TherapyDevelopmental Epileptic EncephalopathiesGlobal Developmental Delay AssessmentMetabolic EncephalopathyMetabolic Epilepsies In ChildrenMyoclonic Encephalopathy Of InfancyMyoclonic SeizuresPhosphate DeficiencyPyridoxal Phosphate-dependent Epilepsy
Pyridox(am)ine phosphate oxidase (PNPO) deficiency causes severe early infantile epileptic encephalopathy and has been characterized as responding to pyridoxal-5'-phosphate but not to pyridoxine. Two males with PNPO deficiency and novel PNPO mutations are reported and their clinical, metabolic, and video-electroencephalographic (EEG) findings described. The first child showed electro-clinical responses to pyridoxine and deterioration when pyridoxine was withheld. At last review, he has well-controlled epilepsy with pyridoxal-5'-phosphate monotherapy and an autism spectrum disorder. The second child had a perinatal middle cerebral artery infarct and a myoclonic encephalopathy. He failed to respond to pyridoxine but responded well to pyridoxal-5'-phosphate. At the age of 21 months he has global developmental delay and hemiparesis but is seizure-free with pyridoxal-5'-phosphate monotherapy. Plasma and cerebrospinal fluid pyridoxamine levels were increased in both children during treatment with pyridoxine or pyridoxal-5'-phosphate. These observations indicate that differential responses to pyridoxine and pyridoxal-5'-phosphate treatment cannot be relied upon to diagnose PNPO deficiency.
14
Bernhard Schmitt, Matthias R. Baumgartner, Philippa B. Mills et al. · Developmental Medicine & Child Neurology · 2010 · 107 citations · Full text
Medicine, Neurology, Pediatrics +17
Neonatal epileptic encephalopathy
RAH Surtees, Catherine DeVile, SJR Heales · The Lancet · 2003 · 86 citations